Literature DB >> 11182251

Elevated activity of phospholipid biosynthetic enzymes in substantia nigra of patients with Parkinson's disease.

B M Ross1, N Mamalias, A Moszczynska, A H Rajput, S J Kish.   

Abstract

We reported that the activities of phospholipase A2, phosphocholine cytidylyltransferase and phosphoethanolamine cytidylyltransferase, key phospholipid metabolic enzymes, are low in substantia nigra of normal human brain and that this might reduce the ability of nigral neurons to repair damage to cell membranes. To determine whether adaptive changes in nigral phospholipid metabolism can occur in idiopathic Parkinson's disease we compared activities of 11 catabolic and anabolic enzymes in autopsied brain of 10 patients with Parkinson's disease to those in control subjects. Nigral activity of the catabolic enzyme phospholipase A2 was normal in the Parkinson's disease group, whereas that of the biosynthetic enzymes phosphoethanolamine cytidylyltransferase, phosphocholine cytidylyltransferase, and phosphatidylserine synthase were elevated 193, 48 and 38%, respectively, possibly representing a compensatory response to repair membrane phospholipids. Enzyme activities were normal in all other brain areas with the exception of increased (+26%) activity of calcium-stimulated phospholipase A2 in putamen, a change which could be consequent to either decreased dopaminergic striatal input or to a dopamine nerve terminal degenerative process. Our data indicate that the normally low rate of membrane phospholipid synthesis in the substantia nigra, the primary area of neurodegeneration in Parkinson's disease, is increased during the course of the disorder. We suggest that pharmacotherapies which augment this compensatory response might have utility as a treatment for Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11182251     DOI: 10.1016/s0306-4522(00)00501-7

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  21 in total

1.  Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease.

Authors:  Noemí Fabelo; Virginia Martín; Gabriel Santpere; Raquel Marín; Laia Torrent; Isidre Ferrer; Mario Díaz
Journal:  Mol Med       Date:  2011-06-22       Impact factor: 6.354

Review 2.  Parkinson's disease: proteinopathy or lipidopathy?

Authors:  Saranna Fanning; Dennis Selkoe; Ulf Dettmer
Journal:  NPJ Parkinsons Dis       Date:  2020-01-03

3.  Brain arachidonic acid cascade enzymes are upregulated in a rat model of unilateral Parkinson disease.

Authors:  Ho-Joo Lee; Richard P Bazinet; Stanley I Rapoport; Abesh Kumar Bhattacharjee
Journal:  Neurochem Res       Date:  2009-12-08       Impact factor: 3.996

4.  Melittin stimulates fatty acid release through non-phospholipase-mediated mechanisms and interacts with the dopamine transporter and other membrane-spanning proteins.

Authors:  Dove J Keith; Amy J Eshleman; Aaron Janowsky
Journal:  Eur J Pharmacol       Date:  2010-10-20       Impact factor: 4.432

Review 5.  Imaging brain signal transduction and metabolism via arachidonic and docosahexaenoic acid in animals and humans.

Authors:  Mireille Basselin; Epolia Ramadan; Stanley I Rapoport
Journal:  Brain Res Bull       Date:  2011-12-09       Impact factor: 4.077

6.  PGE2 EP1 receptor deletion attenuates 6-OHDA-induced Parkinsonism in mice: old switch, new target.

Authors:  Abdullah Shafique Ahmad; Takayuki Maruyama; Shuh Narumiya; Sylvain Doré
Journal:  Neurotox Res       Date:  2013-02-06       Impact factor: 3.911

7.  In vivo imaging of disturbed pre- and post-synaptic dopaminergic signaling via arachidonic acid in a rat model of Parkinson's disease.

Authors:  Abesh Kumar Bhattacharjee; Lindsey M Meister; Lisa Chang; Richard P Bazinet; Laura White; Stanley I Rapoport
Journal:  Neuroimage       Date:  2007-06-27       Impact factor: 6.556

8.  Phosphatidylethanolamine deficiency disrupts α-synuclein homeostasis in yeast and worm models of Parkinson disease.

Authors:  Shaoxiao Wang; Siyuan Zhang; Liang-Chun Liou; Qun Ren; Zhaojie Zhang; Guy A Caldwell; Kim A Caldwell; Stephan N Witt
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-08       Impact factor: 11.205

9.  The citicoline brain injury treatment (COBRIT) trial: design and methods.

Authors:  Ross Zafonte; William T Friedewald; Shing M Lee; Bruce Levin; Ramon Diaz-Arrastia; Beth Ansel; Howard Eisenberg; Shelly D Timmons; Nancy Temkin; Thomas Novack; Joseph Ricker; Randall Merchant; Jack Jallo
Journal:  J Neurotrauma       Date:  2009-12       Impact factor: 5.269

10.  Mitochondrial Dysfunction: The Road to Alpha-Synuclein Oligomerization in PD.

Authors:  A R Esteves; D M Arduíno; D F F Silva; C R Oliveira; S M Cardoso
Journal:  Parkinsons Dis       Date:  2011-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.